Sign in
Rosiglitazone as a therapeutic agent to reduce inflammatory risk in type 2 diabetic patients
Conference proceeding   Peer reviewed

Rosiglitazone as a therapeutic agent to reduce inflammatory risk in type 2 diabetic patients

A. L. Harte, Nasser M Al-Daghri, Khalid Al-Rubeaan, Omar S Al-Attas, N. F da Silva, Shaun Sabico, Sudhesh Kumar and P. G. McTernan
09/2007

Abstract

RC Internal medicine

Details